# Nuclide record erasmus-mc (institution). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/institutions/erasmus-mc/>
  a schema:MedicalOrganization ;
  nuclide:kind "institution" ;
  schema:identifier "erasmus-mc" ;
  schema:name "Erasmus MC Cancer Institute"@en ;
  schema:alternateName "Erasmus MC"@en, "Daniel den Hoed"@en, "Erasmus University Medical Center"@en ;
  schema:description "Rotterdam's OECI-accredited comprehensive cancer centre, where peptide receptor radionuclide therapy with lutetium-177 was pioneered and Europe's largest screening trials were led."@en ;
  schema:url <https://nuclide.cc/institutions/erasmus-mc/>, <https://www.erasmusmc.nl/en/cancer-institute> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:citation <https://www.erasmusmc.nl/en/cancer-institute>, <https://www.hollandptc.nl> ;
  schema:addressCountry "NL" ;
  schema:addressLocality "Rotterdam" ;
  schema:latitude "51.91"^^xsd:decimal ;
  schema:longitude "4.468"^^xsd:decimal ;
  nuclide:related <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:indications <https://nuclide.cc/indications/neuroendocrine/>, <https://nuclide.cc/indications/prostate/>, <https://nuclide.cc/indications/glioblastoma/> ;
  nuclide:technologies <https://nuclide.cc/technologies/radioligand-therapy/>, <https://nuclide.cc/technologies/spect/>, <https://nuclide.cc/technologies/pet-ct/>, <https://nuclide.cc/technologies/ct/> ;
  nuclide:targets <https://nuclide.cc/targets/sstr2/> ;
  nuclide:drugs <https://nuclide.cc/drugs/lutathera/> ;
  nuclide:companies <https://nuclide.cc/companies/novartis/> ;
  nuclide:terms <https://nuclide.cc/terms/theranostics/> .